All In Biotech

Drug Trial Radar · NCT03138512

A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney

A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse

Last checked: Nov 20, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,641 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,641

Actual

Start

Jul 7, 2017

Primary completion

Sep 28, 2023

Study completion Feb 1, 2024

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
May 3, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether nivolmab alone or the combination of nivolumab and ipilimumab versus placebo, is safe and effective for delaying or preventing recurrence of cancer in participants who have experienced partial or entire removal of a kidney.

Conditions

  • Carcinoma, Renal Cell

Interventions

  • nivolumabBiological

    Specified dose on specified days

  • ipilimumabBiological

    Specified dose on specified days

  • nivolumab placeboDrug

    Specified dose on specified days

  • ipilimumab placeboDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-Free Survival (DFS) by BICR - Treatment Part A and BTime frame: From randomization to development of local disease recurrence, distance metastasis, or death, whichever came first (up to approximately 72 months)

Locations

200 sites in 25 countries. Site status is shown where the registry gives one.

  • Local Institution - 0019

    Birmingham, Alabama

  • Local Institution - 0056

    Springdale, Arkansas

  • Local Institution - 0186

    Los Angeles, California

  • Local Institution - 0180

    Los Angeles, California

  • Local Institution - 0002

    San Francisco, California

  • Local Institution - 0185

    Aurora, Colorado

  • Local Institution - 0016

    Athens, Georgia

  • Local Institution - 0005

    Chicago, Illinois

  • Local Institution

    Chicago, Illinois

  • Local Institution - 0006

    St Louis, Missouri

  • Local Institution - 0012

    Howell Township, New Jersey

  • Local Institution - 0007

    Buffalo, New York

  • Local Institution - 0181

    New York, New York

  • Local Institution - 0001

    New York, New York

  • Local Institution - 0008

    Columbus, Ohio

  • Local Institution - 0009

    Portland, Oregon

  • Local Institution - 0010

    Allentown, Pennsylvania

  • Local Institution - 0014

    Greenville, South Carolina

  • Local Institution - 0013

    Chattanooga, Tennessee

  • Local Institution - 0183

    Nashville, Tennessee

  • Local Institution - 0057

    Fairfax, Virginia

  • Local Institution - 0179

    Buenos Aires, Argentina

  • Local Institution - 0099

    CABA, Argentina

  • Local Institution - 0096

    Córdoba, Argentina

  • Local Institution - 0098

    Córdoba, Argentina

  • Local Institution - 0164

    San Juan, Argentina

  • Local Institution - 0097

    San Miguel de Tucumán, Argentina

  • Local Institution - 0178

    Capital Federal, Buenos Aires, Argentina

  • Local Institution - 0126

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Local Institution - 0203

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Local Institution - 0095

    Mar del Plata, Buenos Aires, Argentina

  • Local Institution - 0208

    Mar del Plata, Buenos Aires, Argentina

  • Local Institution - 0173

    Río Cuarto, Córdoba Province, Argentina

  • Local Institution - 0232

    Bariloche, Río Negro Province, Argentina

  • Local Institution - 0215

    Macquarie Park, New South Wales, Australia

  • Local Institution - 0032

    Northmead, New South Wales, Australia

  • Local Institution - 0036

    Randwick, New South Wales, Australia

  • Local Institution - 0035

    St Leonards, New South Wales, Australia

  • Local Institution - 0113

    South Brisbane, Queensland, Australia

  • Local Institution - 0213

    Southport, Queensland, Australia

Showing 40 of 200 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.